Table 4.
Longitudinal cognitive function and cerebrospinal fluid data in 134 Parkinson's disease patients, in relation to COMT Val158Met‐ and DRD2 C957T genotype
| Cognitive domain | Mean difference, measured in SDs (95% CI) | P‐value |
|---|---|---|
| COMT 158Val/Val genotype vs. any Met allele | ||
| Episodic memory | −0.05 (−0.25‐0.15) | .598 |
| Working memory | −0.14 (−0.53‐0.25) | .482 |
| Attention | −0.18 (−0.20‐0.56) | .350 |
| Executive function | −0.19 (−0.51‐0.13) | .245 |
| Visuospatial function | −0.20 (−0.62‐0.22) | .343 |
| DRD2 957T/T genotype vs. any C allele | ||
| Episodic memory | −0.25 (−0.43 to −0.07) | .007a |
| Free recall | −0.42 (−0.78 to −0.07) | .021a |
| Cued recall | 0.36 (0.04‐0.67) | .026a |
| Working memory | −0.33 (−0.69‐0.01) | .060 |
| Attention | −0.58 (−0.91 to −0.26) | <.001a |
| Executive function | −0.31 (−0.61 to −0.02) | .034 |
| Visuospatial function | −0.38 (−0.75 to −0.01) | .044 |
| Cerebrospinal fluid NFL concentration | Difference, ng/L (95% CI) | P‐value |
|---|---|---|
| COMT 158Val/Val genotype vs. any Met allele | 3.8 (−433.0‐440.7) | .986 |
| DRD2 957T/T genotype vs. any C allele | 265.2 (−125.7‐656.1) | .181 |
Fixed effects estimates for differences at 0, 1, 3, 5, and 8 years (for NFL concentration at 0, 1, and 3 years), after correction for age, sex, disease duration, time of testing, and years of education.
a
Significant (P < 0.05) after Holm‐Bonferroni correction.
COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; SD, standard deviation; NFL, neurofilament light chain protein.